Abaco Capital (ABA LN) Business update: likely capital return to shareholders | Clinigen Group (CLIN LN) In line H1, but FX and weak CTS take the shine off H2 | Conviviality (CVR LN) Feedback post round table meeting | Devro (DVO LN) Plenty of positives in FY17 finals | Dialight (DIA LN) Looking for a better buying opportunity | dotdigital Group (DOTD LN) Progress on all fronts | Elementis (ELM LN) A year of progress and a promising outlook for FY18 | James Fisher & Sons (FSJ LN) Solid results: Offshore oil improving | PCI-PAL (PCIP LN) Major US reseller agreement and end-user contract award | Realm Therapeutics (RLM LN) Two new US patents, IP estate expanded into autoimmune disease | Summit Therapeutics (SUMM LN) Additional positive data from the PhaseOut DMD trial | Swallowfield (SWL LN) Strategy bears fruit, brand acquisition-led upgrades | Vectura Group (VEC LN) Upgrade to Buy on valuation grounds | Verona Pharma (VRP LN) FY2017 results in line: Phase II data imminent in Cystic Fibrosis & COPD
